Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 68
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Health Qual Life Outcomes ; 14(1): 153, 2016 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-27809934

RESUMEN

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.


Asunto(s)
Hepatitis B Crónica , Calidad de Vida , Adulto , Anciano , Antivirales/uso terapéutico , Estudios Transversales , Femenino , Indicadores de Salud , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/psicología , Humanos , Entrevistas como Asunto , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Turquía
2.
Neurol India ; 64(5): 896-905, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27625226

RESUMEN

AIMS: There is no report on the factors affecting the resolution of symptoms related to meningitis during treatment of tuberculous meningitis (TBM). Thus, we examined the factors associated with early therapeutic responses. MATERIALS AND METHODS: This multicenter study included 507 patients with microbiologically confirmed TBM. However, 94 patients eligible for the analysis were included in this study from 24 centers. Six out of 94 patients died and the statistical analysis was performed with 88 survivors. Early and late responder groups were compared in the statistical analysis. P < 0.05 were considered to show a significant difference. RESULTS: In the multivariate analysis, the presence of vasculitis (P = 0.029, OR = 10.491 [95% CI, 1.27-86.83]) was found to be significantly associated with a delayed fever response whereas hydrocephalus was associated with altered mental status for >9 days duration (P = 0.005, OR = 5.740 [95% CI, 1.68-19.57]). According to linear regression analysis, fever was significantly persisting (>7 days) in the presence of vasculitis (17.5 vs. 7, P< 0.001) and hydrocephalus (11 vs. 7, P = 0.029). Hydrocephalus was significantly associated with persisting headache (21 vs. 12, P = 0.025), delayed recovery of consciousness (19.5 vs. 7, P = 0.001), and a delay in complete recovery (21 vs. 14, P = 0.007) in the linear regression analysis. Following institution of treatment, the complaints seemed to disappear in up to 2 weeks among TBM survivors. CONCLUSIONS: In the absence of hydrocephalus or vasculitis, one week of anti-tuberculosis treatment seems to be adequate for the resolution of TBM symptoms. Hydrocephalus and vasculitis delay the resolution of TBM symptoms in response to antimycobacterial treatment.


Asunto(s)
Antituberculosos/uso terapéutico , Hidrocefalia/complicaciones , Tuberculosis Meníngea/tratamiento farmacológico , Vasculitis/complicaciones , Humanos , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Tuberculosis Meníngea/complicaciones
3.
Antimicrob Agents Chemother ; 59(6): 3084-9, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25779579

RESUMEN

Data in the literature regarding the factors that predict unfavorable outcomes in adult herpetic meningoencephalitis (HME) cases are scarce. We conducted a multicenter study in order to provide insights into the predictors of HME outcomes, with special emphasis on the use and timing of antiviral treatment. Samples from 501 patients with molecular confirmation from cerebrospinal fluid were included from 35 referral centers in 10 countries. Four hundred thirty-eight patients were found to be eligible for the analysis. Overall, 232 (52.9%) patients experienced unfavorable outcomes, 44 died, and 188 survived, with sequelae. Age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02 to 1.05), Glasgow Coma Scale score (OR, 0.84; 95% CI, 0.77 to 0.93), and symptomatic periods of 2 to 7 days (OR, 1.80; 95% CI, 1.16 to 2.79) and >7 days (OR, 3.75; 95% CI, 1.72 to 8.15) until the commencement of treatment predicted unfavorable outcomes. The outcome in HME patients is related to a combination of therapeutic and host factors. This study suggests that rapid diagnosis and early administration of antiviral treatment in HME patients are keys to a favorable outcome.


Asunto(s)
Antivirales/uso terapéutico , Encefalitis por Herpes Simple/diagnóstico , Encefalitis por Herpes Simple/tratamiento farmacológico , Adulto , Intervalos de Confianza , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
4.
Ann Clin Microbiol Antimicrob ; 14: 30, 2015 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-26018030

RESUMEN

Ebola virus disease (EVD) is a potentially fatal haemorrhagic disease of humans. The last and most serious outbreak of Ebola virus (EBOV) started in December 2013 in West Africa and also affected other continents. Animals such as fruit bats and non-human primates are potential sources of EBOV. This review highlights the clinical features of EVD in humans and animals and addresses the public health implications of EVD outbreaks from the veterinary perspective.


Asunto(s)
Ebolavirus/fisiología , Fiebre Hemorrágica Ebola/veterinaria , Fiebre Hemorrágica Ebola/virología , África Occidental/epidemiología , Animales , Ebolavirus/genética , Fiebre Hemorrágica Ebola/epidemiología , Humanos
5.
Ann Clin Microbiol Antimicrob ; 14: 54, 2015 Dec 21.
Artículo en Inglés | MEDLINE | ID: mdl-26690093

RESUMEN

BACKGROUND: Leptospirosis is a common zoonotic infection in the world. In patients with leptospirosis, in case of presence of Systemic Inflammatory Response Syndrome (SIRS), clinical and laboratory findings can be mistaken for sepsis due to other causes of infection. The purpose of this study is to assess the clinical and laboratory parameters of patients with leptospirosis in terms of the presence of SIRS and to examine the association of these with mortality. METHODS: One hundred fifty-seven patients were included in the study. The patients were classified according to the presence or absence of SIRS and divided into SIRS (+) and SIRS (-). Patient files were retrospectively evaluated. Clinical features and laboratory data were compared, and risk factors associated with mortality were determined. RESULTS: SIRS (+) was found in 70 % (n = 110) of patients who had signs on admission. Comparison of the clinical symptoms and findings of organ systems in the SIRS (+) and SIRS (-) showed that abdominal pain and vomiting were significantly more common in the SIRS (+) than in the SIRS (-) (p = 0.025 and p = 0.046, respectively). BUN and serum creatinine levels were significantly higher in the SIRS (+) than in the SIRS (-) (p = 0.002 and p < 0.001, respectively). In follow-up posterior-anterior chest radiography, pathological findings improved in 58.8 % (n = 40) of patients in the SIRS (+) and 27.3 % (n = 9) of patients in the SIRS (-) (p = 0.003). The mortality rate of the SIRS (+) and SIRS (-) was not significantly different (p = 0.868). CONCLUSION: In patients with positive SIRS findings, while examining the etiology of sepsis, leptospirosis should come to mind especially in endemic areas for differential diagnosis. Early initiation of antibiotic and supportive therapy can be lifesaving in these patients.


Asunto(s)
Leptospirosis/complicaciones , Leptospirosis/patología , Síndrome de Respuesta Inflamatoria Sistémica/patología , Dolor Abdominal/epidemiología , Dolor Abdominal/etiología , Adolescente , Adulto , Anciano , Creatinina/sangre , Femenino , Humanos , Leptospirosis/diagnóstico , Leptospirosis/mortalidad , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de Supervivencia , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/mortalidad , Vómitos/epidemiología , Vómitos/etiología , Adulto Joven
6.
Ann Clin Microbiol Antimicrob ; 14: 47, 2015 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-26538030

RESUMEN

BACKGROUND: Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. METHODS: Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). RESULTS: Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any first-line drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38-6.82) and 2.14 (95 % CI, 0:34-13:42), respectively. CONCLUSION: INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Meníngea/microbiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Líquido Cefalorraquídeo/microbiología , Europa (Continente)/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Prevalencia , Estudios Retrospectivos , Análisis de Supervivencia , Tuberculosis Meníngea/epidemiología , Tuberculosis Meníngea/mortalidad , Adulto Joven
7.
Intervirology ; 56(3): 201-5, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23548552

RESUMEN

BACKGROUND/AIMS: Molecular epidemiology of hepatitis C virus (HCV) shows that HCV genotypes are unique with respect to their nucleotide sequence, geographical distribution and clinical relationship. METHODS: In this study we enrolled 67 HCV-infected individuals with various stages of liver disease from four geographical regions of Turkey. A partial NS5B region of the HCV genome was sequenced and subjected to phylogenetic analysis to determine the circulating HCV genotypes and subtypes. RESULTS: The results showed that HCV genotype 1 (subtype1b) is the main genetic variant of HCV in Turkey but did not reveal any Turkish indigenous phylogenetic cluster. Phylogenetic analysis showed that Turkish strains have their closest matches from both Asia (Japan) and Europe/USA. CONCLUSIONS: In view of Turkey's geographic position, HCV-1b transmission from Europe is not exceptional. This study could not establish a clear role of other HCV genotypes prevalent in neighboring Asian countries in Turkey's HCV transmission, which would need to be confirmed by further regional epidemiological studies.


Asunto(s)
Variación Genética , Hepacivirus/clasificación , Hepacivirus/genética , Hepatitis C/epidemiología , Hepatitis C/virología , Adulto , Anciano , Análisis por Conglomerados , Femenino , Genotipo , Hepacivirus/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Epidemiología Molecular , Filogenia , Análisis de Secuencia de ADN , Turquía/epidemiología , Proteínas no Estructurales Virales/genética
8.
Microbiol Immunol ; 57(2): 122-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23252849

RESUMEN

The role of hepatitis B virus (HBV) genetics in the clinical manifestations of infection is being increasingly recognized. Genotype D is one of eight currently recognized major HBV genotypes. The virus is ubiquitous worldwide, but shows different features in different regions. One hundred and ninety-eight patients with chronic HBV infection were enrolled in this study, 38 of whom had been diagnosed with cirrhosis of the liver and/or hepatocellular carcinoma. HBV DNA was isolated from the patients' blood samples and the entire genome and/or the basal core promoter/core promoter region sequenced. Phylogenetic analysis of the complete genomes revealed that subgenotype D1 is the most prevalent subgenotype in Turkey, but there was no definite phylogenetic grouping according to geography for isolates from different regions within Turkey, or for isolates in Turkey relative to other parts of the world. Turkish isolates tended to be genetically similar to European and central Asian isolates. Overall, HBV-infection in Turkey appears to be characterized by early HBeAg seroconversion, a high incidence of the A1896 core promoter mutation and a small viral load. Genotype D characteristic mutations A1757 and T1764/G1766 were found in the BCP region. T1773 was associated with T1764/G1766 and a larger viral load. In conclusion, infection with HBV genotype D in Turkey has a similar clinical outcome to that of Europe and central Asia. Genotypic mutations in genotype D may be linked with disease prognosis in Turkey, but further studies with higher sample numbers and balanced clinical groups are needed to confirm this.


Asunto(s)
Virus de la Hepatitis B/genética , Virus de la Hepatitis B/patogenicidad , Hepatitis B Crónica/epidemiología , Hepatitis B Crónica/virología , Mutación , Regiones Promotoras Genéticas , Adolescente , Adulto , Anciano , Femenino , Genotipo , Virus de la Hepatitis B/clasificación , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Filogenia , Prevalencia , Análisis de Secuencia de ADN , Turquía/epidemiología , Adulto Joven
11.
Clin Lab ; 58(3-4): 273-80, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22582501

RESUMEN

BACKGROUND: Oxidative stress is defined as a disturbance of balance between free radicals and antioxidant defense system. This study investigated oxidative stress in patients with chronic hepatitis B. METHODS: Sixty nine patients with chronic hepatitis B admitted to the Department of the Infectious Diseases and Clinical Microbiology of Medical Faculty of Ondokuz Mayis University were enrolled into study. Twenty healthy persons were included as a control group. The study group was divided into three groups: healthy controls (group 1), chronic hepatitis B (group 2), and inactive hepatitis B carriers (group 3). Antioxidant status of plasma, including glutathione, glutathione peroxidase, vitamin E, and vitamin C levels were measured. Carbonyl and lipid peroxidation levels were measured as parameters of oxidative stress. RESULTS: Glutathione, glutathione peroxidase, vitamin E, and vitamin C levels were found to be significantly decreased in the chronic hepatitis B group when compared with the control group (9.5 vs. 13.8, p < 0.05; 22.98 vs. 32.4, p < 0.05; 15.1 vs. 16.4, p < 0.05; 12.9 vs. 18.4, p < 0.05, respectively). Carbonyl and lipid peroxidation levels were significantly increased in the chronic hepatitis B group compared to controls (0.7 vs. 0.5, p < 0.05; 2 vs. 0.7, p < 0.05, respectively). However, whereas the glutathione and carbonyl level correlation with HBV DNA levels were mild to moderate (glutathione vs. HBV DNA, r:-0.288, p < 0.05; carbonyl vs. HBV DNA, r:0.317, p < 0.05), the lipid peroxidation levels were strongly related with HBV DNA levels in chronic hepatitis B (r:0.545, p < 0.05). CONCLUSIONS: Oxidative stress was significantly increased in hepatitis B patients. Consequently, decreases were seen at the level of protective antioxidative parameters in the blood of these patients.


Asunto(s)
Portador Sano/metabolismo , Hepatitis B Crónica/metabolismo , Peroxidación de Lípido , Estrés Oxidativo , Adulto , Ácido Ascórbico/sangre , Portador Sano/virología , Estudios de Casos y Controles , Femenino , Glutatión/sangre , Glutatión Peroxidasa/sangre , Hepatitis B Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Carbonilación Proteica , Carga Viral , Vitamina E/sangre
12.
Mikrobiyol Bul ; 46(1): 1-8, 2012 Jan.
Artículo en Turco | MEDLINE | ID: mdl-22399165

RESUMEN

Pseudomonas aeruginosa which is a common cause of nosocomial infections, usually leads to treatment difficulties due to multi-drug resistance. PER-1 type extended-spectrum beta-lactamase (ESBL) producing bacteria are shown to be common in Turkey. Since limited number of antibiotics such as antipseudomonal penicillins, cephalosporins, aminoglycosides, fluoroquinolones and carbapenems are available for the treatment of P.aeruginosa infections, it is essential to monitor and eventually control the spread of antibiotic resistance genes. The aims of this study were to investigate the presence of PER-1 type ESBLs in nosocomial P.aeruginosa isolates and to evaluate their resistance to some commonly used antibiotics. A total of 110 P.aeruginosa strains isolated from clinical samples [40 urine, 26 exudate, 20 blood, 24 others (sputum, tracheal aspirate, tissue biopsy, cerebrospinal fluid, pleural fluid, conjunctiva)] of the inpatients who were proven to have nosocomial infections in Ondokuz Mayis University Faculty of Medicine Hospital between May 2002-June 2003 were included in the study. Identification of the isolates was performed by ATB system ID 32 GN (bio-Merieux, France). Antibiotic susceptibilities were detected by standard disk diffusion method and PER-1 type ESBL was searched by polymerase chain reaction using PER-1 and PER- 2 primers. PER-1 positivity was detected in 62 of 110 (56.4%) P.aeruginosa isolates and 51 of 65 (78.5%) ceftazidime-resistant strains. The highest susceptibility rate was detected for ciprofloxacin (76.4%), while the lowest susceptibility rate was for ticarcillin-clavulanic acid (22.7%). Rates of resistance to beta-lactam agents (excluding piperacillin/tazobactam), amikacin and gentamicin were statistically significantly higher for PER-1 positive strains than PER-1 negative ones. Resistance rates to ceftazidime, cefepime, aztreonam, piperacillin and ticarcillin-clavulanic acid in PER-1 positive isolates versus negative ones were as 82.3% vs. 29.2% (p< 0.01), 75.8% vs. 25% (p< 0.01), 83.9% vs. 30.4% (p< 0.01), 73.8% vs. 52.2% (p< 0.05), 85.5% vs. 66.7% (p< 0.05), respectively. Considering resistance rates to piperacillin-tazobactam and ciprofloxacin, PER-1 positive isolates versus negatives were 35.5% vs. 31.3%, and 19.4% vs. 29.2%, respectively, revealing no statistical significance (p> 0.05). As a result, PER-1 type ESBL frequency and beta- lactam and aminoglycoside resistance rates were found remarkably high in nosocomial P.aeruginosa strains isolated in our hospital. It was concluded that antibiotic resistance should be continously monitorized and necessary measures to prevent further increase in resistance should be promptly established.


Asunto(s)
Infección Hospitalaria/microbiología , Farmacorresistencia Bacteriana , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , beta-Lactamasas/análisis , Antibacterianos/farmacología , Humanos , Pseudomonas aeruginosa/enzimología , Pseudomonas aeruginosa/aislamiento & purificación , Turquía
13.
Mikrobiyol Bul ; 46(3): 470-4, 2012 Jul.
Artículo en Turco | MEDLINE | ID: mdl-22951659

RESUMEN

Treatment of catheter-associated infections caused by Staphylococcus aureus is difficult without catheter removal, because of the biofilm formation and its high virulence. In this report, we presented our clinical and microbiological experience with systemic daptomycin (6 mg/kg/on alternate days IV) as well as antibiotic lock therapy (filling of the catheter lumen with 3.5 mg/ml daptomycin together with 0.045 mg/ml calcium) in the treatment of a catheter-associated bloodstream infection caused by methicillin-resistant S.aureus in a patient with hemodialysis catheter which could not be removed.


Asunto(s)
Antibacterianos/administración & dosificación , Bacteriemia/tratamiento farmacológico , Infecciones Relacionadas con Catéteres/tratamiento farmacológico , Daptomicina/administración & dosificación , Staphylococcus aureus Resistente a Meticilina , Infecciones Estafilocócicas/tratamiento farmacológico , Bacteriemia/microbiología , Infecciones Relacionadas con Catéteres/microbiología , Femenino , Humanos , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Persona de Mediana Edad , Diálisis Renal/efectos adversos , Diálisis Renal/instrumentación , Infecciones Estafilocócicas/microbiología
14.
Travel Med Infect Dis ; 44: 102148, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34454090

RESUMEN

BACKGROUND: Increasing number of patients with COVID-19-associated mucormycosis have been reported, especially from India recently. We have described a patient with COVID-19-associated mucormycosis and, searched and analyzed current medical literature to delineate the characteristics of COVID-19-associated mucormycosis. METHOD: We reported a patient developed mucormycosis during post-COVID period. We searched literature to describe the incidence, clinical features, and outcomes of COVID-19-associated mucormycosis. Demographic features, risk factors, clinical features, diagnostic methods, treatment and outcome were analyzed. RESULTS: We describe a 54-year-old male, hospitalized due to severe COVID-19 pneumonia. He was given long-term, high doses of systemic steroids. He developed maxillo-fascial mucormycosis and died of sepsis. Our literature search found 30 publications describing 100 patients including present case report. The majority (n = 68) were reported from India. 76% were male. The most commonly seen risk factors were corticosteroid use (90.5%), diabetes (79%), and hypertension (34%). Also, excessive use of broad-spectrum antibiotics were noted in cases. Most frequent involvements were rhino-orbital (50%), followed by rhino-sinusal (17%), and rhino-orbito-cerebral (15%). Death was reported as 33 out of 99 patients (33,3%). CONCLUSIONS: Steroid use, diabetes, environmental conditions, excessive use of antibiotics, and hypoxia are main risk factors. Despite medical and surgical treatment, mortality rate is high. A multidisciplinary approach is essential to improve the conditions facilitating the emergence of COVID-19-associated mucormycosis.


Asunto(s)
COVID-19 , Mucormicosis , Humanos , Masculino , Persona de Mediana Edad , Incidencia , Mucormicosis/diagnóstico , Mucormicosis/tratamiento farmacológico , Factores de Riesgo , SARS-CoV-2
15.
Mikrobiyol Bul ; 43(1): 159-62, 2009 Jan.
Artículo en Turco | MEDLINE | ID: mdl-19334394

RESUMEN

Pseudomonas stutzeri which is an aerobic, non-fermentative gram-negative bacillus frequently found in soil, water and hospital environment, rarely leads to serious community-acquired infections. In this report a case of community-acquired meningitis due to P. stutzeri was presented. A 73-years-old male patient was admitted to the emergency department with the complaints of nausea, vomiting, headache, dizziness, difficulties in walking and speaking and loss of consciousness. There was no history of an underlying disease or immunosuppression. Physical examination revealed nuchal rigidity, however, Kernig and Brudzinski signs were negative. The cerebrospinal fluid (CSF) analysis revealed 0.4 mg/dl glucose (simultaneous blood glucose 145 mg/dl), and 618 mg/dl protein and 640 leucocyte/mm3 (90% PMNL). No bacteria were detected in Gram stained and Ehrlich-Ziehl-Neelsen stained CSF smears. Upon the diagnosis of acute bacterial meningitis, treatment with ceftriaxone and ampicillin was initiated, however, the patient died after 16 hours of hospitalization. CSF culture yielded the growth of gram-negative oxidase-positive bacteria and the isolate was identified as P. stutzeri by Vitek-2 Compact system (bioMerieux, France). The isolate was found to be sensitive to piperacillin/tazobactam, amikacin, gentamycin, ceftazidime, cefepime, ciprofloxacin, imipenem and meropenem. Since the patient was lost due to acute respiratory and cardiac failure, it was not possible to change the therapy to agent specific therapy. In conclusion, it should always be kept in mind that uncommon agents could lead to community-acquired meningitis in elderly patients and empirical treatment protocols might fail in such cases resulting in high morbidity and mortality.


Asunto(s)
Inmunocompetencia , Infecciones por Pseudomonas/microbiología , Pseudomonas stutzeri/aislamiento & purificación , Anciano , Ampicilina/uso terapéutico , Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/inmunología , Infecciones Comunitarias Adquiridas/microbiología , Resultado Fatal , Humanos , Masculino , Infecciones por Pseudomonas/diagnóstico , Infecciones por Pseudomonas/inmunología , Pseudomonas stutzeri/efectos de los fármacos
16.
Lancet Infect Dis ; 19(8): 862-871, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31262565

RESUMEN

BACKGROUND: Data describing the coagulopathy of Crimean-Congo haemorrhagic fever are scarce. We did rotational thromboelastometry (ROTEM) and conventional coagulation testing in patients with Crimean-Congo haemorrhagic fever to increase our understanding of the coagulopathy of this infectious disease. METHODS: We did a prospective observational cohort study of adults aged 18 years and older and admitted to hospitals with PCR-confirmed Crimean-Congo haemorrhagic fever in Samsun and Tokat, Turkey. Demographic, clinical, and laboratory data were collected and blood samples for ROTEM analysis and coagulation testing were drawn at admission and during hospital admission and convalescence (up to 30 days after onset of illness). For the ROTEM analysis we recorded the following extrinsically activated ROTEM (EXTEM S) variables, with normal ranges indicated: clotting time (38-79 s), clot formation time (34-159 s), amplitude at 10 min after clotting time (43-65 mm), maximum clot firmness (50-72 mm), and maximum lysis (>15% at 1 h). The following fibrin-specific ROTEM (FIBTEM S) variables were also recorded: amplitude at 10 min after clotting time (normal range 7-23 mm) and maximum clot firmness (9-25 mm). Disease severity was assessed by Swanepoel criteria, severity grading score (SGS), and the severity scoring index (SSI), with mild disease defined as meeting no Swanepoel criteria, graded mild by SSI, and graded low risk by SGS. FINDINGS: Between May 27, 2015, and Aug 2, 2015, 65 patients with confirmed Crimean-Congo haemorrhagic fever were recruited and had blood taken at 110 time points. Most were male (40 [62%] of 65) with mild disease (49 [75%] of 65). Haemorrhage occurred in 13 (20%; 95% CI 11·1-31·8) of 65 patients and 23 (35%) of 65 received blood products (15 received fresh frozen plasma and eight received red blood cell concentrates), and 21 patients received platelet transfusions. At admission, the following EXTEM S variables differed significantly between mild cases and moderate to severe cases: median clotting time 56 s (range 42-81; IQR 48-64) versus 69 s (range 48-164; IQR 54-75; p=0·01); mean amplitude at 10 min after clotting time 45·1 mm (SD 7·0) versus 33·9 mm (SD 8·6; p<0·0001); median clot formation time 147 s (range 72-255; IQR 101-171) versus 197 s (range 98-418; IQR 156-296; p=0·006); and maximum clot firmness 54·4 mm (SD 7·2) versus 45·1 mm (SD 12·5; p=0·003). The EXTEM S variables were compared at different time points; maximum clot firmness (p=0·024) and amplitude at 10 min after clotting time (p=0·090) were lowest on days 4-6 of illness. We found no significant differences in FIBTEM variables between mild and moderate to severe cases (median amplitude at 10 min, 13 mm [range 8-20; IQR 11-15] vs 12 mm [range 6-25; IQR 10-15; p=0·68]; and median maximum clot firmness, 15 mm [range 9-60; IQR 13-21] vs 17 mm [range 7-39; IQR 13-23; p=0·21]); and no hyperfibrinolysis (maximum lysis >15%). INTERPRETATION: Coagulopathy of Crimean-Congo haemorrhagic fever is related to defects in clot development and stabilisation that are more marked in severe disease than in mild disease. The combination of normal and slightly deranged coagulation screens and FIBTEM results with the absence of hyperfibrinolysis suggests that the coagulopathy of Crimean-Congo haemorrhagic fever relates to platelet dysfunction. FUNDING: Wellcome Trust, UK Ministry of Defence, and National Institute for Health Research Health Protection Research Unit.


Asunto(s)
Trastornos de la Coagulación Sanguínea/sangre , Fiebre Hemorrágica de Crimea/diagnóstico , Tromboelastografía , Femenino , Fiebre Hemorrágica de Crimea/sangre , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Turquía
17.
Antiviral Res ; 150: 9-14, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29217468

RESUMEN

BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. RESULTS: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (≤1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. CONCLUSION: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.


Asunto(s)
Hepacivirus , Hepatitis C/diagnóstico , Hepatitis C/tratamiento farmacológico , Antivirales/uso terapéutico , Asia/epidemiología , Diagnóstico por Imagen de Elasticidad , Europa (Continente)/epidemiología , Femenino , Hepatitis C/epidemiología , Hepatitis C/virología , Humanos , Reembolso de Seguro de Salud , Masculino , Prevalencia , Carga Viral
18.
Mikrobiyol Bul ; 41(2): 303-7, 2007 Apr.
Artículo en Turco | MEDLINE | ID: mdl-17682719

RESUMEN

Intracranial aspergillosis is a rare clinical picture, but the mortality rate is very high. In this report, an immunocompetent 43 years old male patient with mortal intracranial aspergillosis was presented. The patient has been admitted to Neurosurgery Clinics of our hospital with the complaints of weakness and walking difficulties. In the cranial tomography a brain mass was detected, and his medical history revealed that he had experienced an operation 18 months ago because of another intracranial tumour. After the operation his fever was high (39 degrees C), the leukocyte count, erythrocyte sedimentation rate and CRP values were increased, and purulent discharge was present in the operation site. As the pathological examination of the operation material have suggested aspergillosis, conventional amphotericin B treatment was started initially, but has changed to liposomal form 18 days later. Aspergillus fumigatus has been grown on the exudate culture collected from flap region. The levels of immunoglobulins and complement components of the patient were found normal. Since his next cranial magnetic resonance result indicated the presence of pansinusitis and destructive lesions in ethmoid sinuses, caspofungin was added to the therapy. The patient has reoperated since there was no clinical and laboratory progress at the 83rd day of amphotericin B, and 10th day of caspofungin therapy. Bacterial and fungal cultures of specimens collected during the second operation yielded negative results, however microabscesses and chronic inflammation focci were detected in histopathological examination. Fever and purulent discharge recurred in the patient after the second operation and visual defect has developed in his left eye. There was no bacterial or fungal growth in the discharge material, but direct microscopy have showed the presence of septate hyphae. The patient was discharged from the hospital by his family request with oral itraconazole treatment, however, he died one month later. Since no immunosuppressive status was detected in our patient, the transmission was thought to occur during the operation which he had experienced one and half year ago. In conclusion, the patients who experience neurosurgery should be followed-up carefully in terms of aspergillosis.


Asunto(s)
Aspergillus fumigatus/aislamiento & purificación , Encefalopatías/diagnóstico , Inmunocompetencia , Neuroaspergilosis/diagnóstico , Infección de la Herida Quirúrgica/diagnóstico , Adulto , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Encefalopatías/tratamiento farmacológico , Encefalopatías/microbiología , Caspofungina , Equinocandinas/uso terapéutico , Resultado Fatal , Humanos , Itraconazol/uso terapéutico , Lipopéptidos , Masculino , Neuroaspergilosis/tratamiento farmacológico , Neuroaspergilosis/etiología , Reoperación , Infección de la Herida Quirúrgica/tratamiento farmacológico , Infección de la Herida Quirúrgica/microbiología
20.
Trop Doct ; 47(1): 71-72, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27486029

RESUMEN

Infective endocarditis (IE) is life-threatening condition with a highly variable clinical presentation. We report a case of acute IE with delayed diagnosis which resulted due to an initial misdiagnosis of Crimean Congo Hemorrhagic Fever (CCHF) in an endemic area. A case was due to Staphylococcus aureus and requiring valve replacement. They serve to emphasize the importance of careful history taking, physical examination and a broad range of different diagnostic techniques in the context of suspected viral hemorrhagic fever.


Asunto(s)
Endocarditis Bacteriana/diagnóstico , Virus de la Fiebre Hemorrágica de Crimea-Congo , Fiebre Hemorrágica de Crimea/diagnóstico , Errores Diagnósticos , Ecocardiografía , Enfermedades Endémicas , Femenino , Humanos , Persona de Mediana Edad , Staphylococcus aureus
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA